meta
|
evidence
oncology
Living systematic review and meta-analysis
breast cancer - HR positive
es-BC - HR positive - (neo)adjuvant (NA)
2
es-BC - HR-positive - 1st line (L1)
1
la/mBC - HR positive
2
la/mBC - HR positive - (neo)adjuvant (NA)
3
la/mBC - HR positive - NA - PIK3CA mutant
la/mBC - HR-positive - 1st line (L1)
13
la/mBC - HR positive - L1 - PIK3CA mutant
1
la/mBC - HR-positive - 2nd line (L2)
20
la/mBC - HR positive - L2 - all population
1
la/mBC - HR positive - L2 - PIK3CA mutant
1
AKT inhibitor
capivasertib based treatment
capivasertib plus paclitaxel
ipatasertib based treatment
ipatasertib plus paclitaxel
cyclin inhibitor
abemaciclib based treatment
abemaciclib plus aromatase inhibitor
abemaciclib plus endocrine therapy
palbociclib based treatment
palbociclib plus endocrine therapy
palbociclib plus letrozole
ribociclib based treatment
ribociclib plus letrozole
HER inhibitor
HER2 inhibitor
trastuzumab based treatment
trastuzumab plus endocrine therapy
TKI anti HER1/EGFR and HER2/neu
lapatinib based treatment
lapatinib plus fulvestrant
lapatinib plus letrozole
IGF-1R inhibitors
dalotuzumab plus ridaforolimus plus exemestane
VEGF(R) inhibitor
cediranib plus fulvestrant
versus all
vs chemotherapy
vs non platinum-based chemotherapy
vs taxanes
vs paclitaxel
vs endocrine therapy
vs aromatase inhibitor
vs exemestane
vs exemestane plus ridaforolimus
vs fulvestrant
vs letrozole
vs HER inhibitor
vs HER2 inhibitor
vs trastuzumab based treatment
vs trastuzumab plus chemotherapy
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
Evidence gap map
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
lapatinib based treatment
lapatinib plus fulvestrant
la/mBC - HR-positive - 1st line (L1)
13
la/mBC - HR positive - L1 - PIK3CA mutant
1
Comparator:
vs fulvestrant;
Risk of bias:
low;
some concerns;
high;
NA;